Physician profile
Arvind Shah
NPI 1639276827
$784.76
in general payments reported to CMS, 2019-2025
17 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $30.95 · 2024: $130 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $225.98 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $130.15 | 2024 | Breztri |
| Orexo US, INC. | $79.55 | 2019 | |
| Indivior INC. | $43.06 | 2019 | |
| Allergan, INC. | $42.75 | 2019 | |
| Ironshore Pharmaceuticals INC. | $33.44 | 2019-2020 | |
| Adlon Therapeutics L.P. | $32.25 | 2019 | |
| Supernus Pharmaceuticals, INC. | $31.81 | 2025 | Qelbree |
| Lundbeck LLC | $26.11 | 2025 | Rexulti |
| Alkermes, INC. | $25.68 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.05 | 2019 | |
| Bausch Health US, LLC | $19.02 | 2025 | Wellbutrin |
| Sunovion Pharmaceuticals INC. | $17.95 | 2019 | |
| Vanda Pharmaceuticals INC. | $17.60 | 2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.95 | 2025 | Caplyta |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $12.50 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.